Esteve A, Martel-Planche G, Sylla B S, Hollstein M, Hainaut P, Montesano R
International Agency for Research on Cancer, Lyon, France.
Int J Cancer. 1996 May 3;66(3):301-4. doi: 10.1002/(SICI)1097-0215(19960503)66:3<301::AID-IJC5>3.0.CO;2-2.
Mutational analysis of the p16/CDKN2 gene was conducted by direct sequencing of the whole coding sequence (exons 1-3 and flanking splicing sites) in 21 esophageal squamous-cell carcinomas and 3 adenocarcinomas from a high-incidence area of Italy. Two inactivating mutations were found in exon 1 of the gene (both in squamous-cell carcinoma), whereas no mutations were detected in exon 2, where most of the sequence changes reported so far have been located, or in exon 3. Southern blot analysis of exon 2 in this set of samples and in a complementary set of 12 tumor samples from France did not show homozygous deletions or detectable gene rearrangements. Thus, p16/CDKN2 gene alterations do not appear to play a major role in the group of patients examined.
通过对来自意大利一个高发病区的21例食管鳞状细胞癌和3例腺癌的整个编码序列(外显子1 - 3及侧翼剪接位点)进行直接测序,对p16/CDKN2基因进行了突变分析。在该基因的外显子1中发现了两个失活突变(均在鳞状细胞癌中),而在外显子2(迄今为止报道的大多数序列变化都位于此处)或外显子3中未检测到突变。对这组样本以及来自法国的12例肿瘤样本的互补组中外显子2进行的Southern印迹分析未显示纯合缺失或可检测到的基因重排。因此,p16/CDKN2基因改变似乎在接受检查的患者群体中不发挥主要作用。